To ensure the benefits of early detection by mammography ([@bib33]; [@bib21]) women with abnormal screening results must have access to timely and accurate diagnostic assessment. One of the essential components of screening centres is appropriate follow-up of women with abnormal findings with an effective referral system ([@bib34]). The time required for assessment of an abnormal mammogram is associated with patient stress and anxiety ([@bib32]; [@bib29]; [@bib7]) and delays in diagnostic times have a negative impact on the prognosis of screen-detected breast cancers ([@bib24]; [@bib14]).

A study of Canadian screening programs found that age at screen, family history of breast cancer, and screening history were not associated with delays in breast cancer diagnosis ([@bib24]). However, this study as well as several others found that diagnostic intervals actually decreased for screened women with high-suspicion mammograms ([@bib10]; [@bib24]; [@bib14]; [@bib3]; [@bib6]). Shorter diagnostic times were also seen for women with higher income ([@bib3]), larger tumour size ([@bib3]), more advanced stage ([@bib18]), and for women who attended screening programs that used core biopsies more often than open biopsies ([@bib22]).

The Ontario Breast Assessment Collaborative Group was established in 1998 to guide development of coordinated multidisciplinary approaches for facilities to provide organised breast assessment ([@bib26]). Within the Ontario Breast Screening Program (OBSP), facilities that qualify as a Breast Assessment Centre (BAC) have a patient navigation system that coordinates referrals through a defined pathway and have access to diagnostic imaging, image-guided biopsies, pathology, and surgical services. Canadian breast screening programs have reported shorter diagnostic intervals for women who had coordinated referrals from screening centres to diagnostic facilities ([@bib23]; [@bib12]; [@bib27]; [@bib6]; [@bib4]). For women screened in the OBSP, a previous study showed that women receiving work-up through organised assessment had shorter diagnostic wait times with a biopsy than for those evaluated through usual care (UC) ([@bib28]). However, this study only utilised 1 year of data, and did not explore the effect of various assessment and prognostic characteristics on diagnostic intervals. A more recent Ontario study of screened women had similar findings; however, a large proportion (20.5%) underwent opportunistic screening and only invasive cancers were included ([@bib18]).

After 15 years of implementation of BACs in the OBSP, this study aims to evaluate the effectiveness of organised breast assessment. Wait times from an abnormal mammogram to breast cancer diagnosis will be compared between concurrent cohorts of women aged 50--69 years screened in the OBSP undergoing assessment through BAC and UC. The association of assessment and prognostic characteristics with wait times will be examined separately in BAC and UC cohorts.

Materials and methods
=====================

Study population
----------------

The OBSP has operated since 1990 to deliver a population-based breast screening program to eligible women ([@bib11]). Women are not eligible if they have had a prior history of breast cancer, an augmentation mammoplasty, or if they currently have acute breast symptoms. This study identified women aged 50--69 years screened through the OBSP with an abnormal mammogram between 1 January 2002 and 31 December 2009. Mammography consisted of standard craniocaudal and mediolateral oblique views performed by certified mammography technologists on equipment that meets or exceeds that specified by Canadian Association of Radiologists' Mammography Accreditation Program (CAR-MAP). Of those with an abnormal mammogram, one cohort underwent diagnostic assessment through a BAC and the other through UC. Although all women in the study were screened at an OBSP centre, referral to a BAC was dependent on whether the screening centre was affiliated with a BAC. Women were then followed prospectively to determine whether there was a breast cancer diagnosis within a year of the abnormal screening mammogram. During the time period of this study, women were screened at 150 OBSP centres and assessed at 35 BACs. The study was approved by the University of Toronto Research Ethics Board and informed consent was not required.

Ontario facilities that provide organised assessment must meet established criteria in order to qualify as a BAC. Criteria include: having certified mammography technologists and equipment that meets or exceeds that specified by CAR-MAP; providing all abnormal mammographic work-up including special mammographic views and image-guided core biopsy; providing radiological, surgical, and pathologic consultation with experts in breast evaluation; and providing a navigator for patient support and coordination of referrals. The BACs may either perform all the required services for abnormal mammographic work-up or establish networks with facilities to provide the services ([@bib28]). For OBSP women seen through UC, further diagnostic imaging after an abnormal mammogram is arranged directly from the screening centre and/or through their physician; results must be communicated to the physician who is then responsible for arranging any necessary biopsy and/or surgical consultation.

Selection of breast cancer cases
--------------------------------

There were 2 147 257 women aged 50--69 years screened at an OBSP centre between 1 January 2002 and 31 December 2009. To allow for learning curves for new BACs, only women with an abnormal mammogram assessed after the first 6 months of operation were selected. All women diagnosed with unilateral, primary ductal carcinoma *in situ* (DCIS), or invasive breast cancer of any histological type were identified through record linkage with the Ontario Cancer Registry (OCR) ([@bib17]). Breast cancers detected within 12 months of the abnormal screening episode and classified as screen-detected by the program during follow-up were included. For these women, the last OBSP abnormal screening mammogram before diagnosis was included. Information for all women screened within the OBSP was obtained from data routinely collected by the Integrated Client Management System (ICMS) and OCR.

### Demographics and breast cancer risk factors

Information on demographics and breast cancer risk factors comprises self-reported data in the ICMS, collected at the screening appointment. Age and year at screen were based on the date of abnormal mammogram before diagnosis. Women with a first-degree relative with breast or ovarian cancer or personal history of ovarian cancer were classified as having a positive family history. Menopausal status (premenopausal, postmenopausal), age at menarche (⩽11 years, \>11 years), and parity (nulliparous; first full-term pregnancy (FFTP) \<30 years; FTTP ⩾30) were also measured. Women's postal code of residence at screening was linked to the 2006 Canadian Census ([@bib35]) to determine socioeconomic status (SES) and community status. The SES was defined by five income quintiles (Q1 (low)--Q5 (high)). Community status included urban (population 10 000+), rural (\<10 000 and a strong metropolitan influenced zone (MIZ)), rural remote (\<10 000 and a moderate MIZ), and rural very remote (\<10 000 and a weak/no MIZ) ([@bib31]).

### Screening characteristics

Information on screening visit for each woman was obtained through the ICMS. An abnormal mammogram was defined as an initial screen for women who had only one OBSP mammogram, or a rescreen for women who had more than one mammogram. The type of mammography was recorded as screen film or digital. Mammographic density was recorded by the radiologist as \<75% or ⩾75%.

### Assessment characteristics

Assessment procedures and dates were obtained through ICMS. Time (days) to a woman's first assessment procedure following an abnormal screening mammogram was calculated. Assessment procedures from abnormal screening mammogram to final diagnosis date included breast imaging (diagnostic mammogram, ultrasound, MRI), breast biopsy (fine-needle aspiration (FNA), core biopsy, open/surgical), and consultation (radiological, surgical, oncology, primary care). Procedures at first visit were categorised hierarchically as consultation only; imaging±consultation (i.e., imaging only, imaging with consultation); and biopsy±consultation or imaging (i.e., biopsy only; biopsy and consultation, biopsy and imaging, biopsy with imaging and consultation). First diagnostic assessment delay was defined as having a first assessment \>3 weeks following an abnormal mammogram ([@bib8]). Number of assessment procedures, number of assessment visits, and average number of procedures per visit were calculated and categorised according to the median. Type of biopsy was defined as the woman's first biopsy procedure after abnormal mammogram and was either percutaneous (FNA, core biopsies) or surgical (open surgical, nodal/axillary, nodal/sentinel, or treatment surgery).

Diagnosis age refers to the age at screen-detected breast cancer diagnosis. Time (days) to breast cancer diagnosis was calculated from the date of the abnormal screening mammogram to the date of the first biopsy indicating malignancy. Diagnostic delay was defined as having a breast cancer diagnosis \>7 weeks after an abnormal screening mammogram, a national timeliness target based on expert opinion and evidence review ([@bib8]; [@bib9]).

### Prognostic characteristics

Histological classification (invasive, DCIS) for breast cancers was obtained from the ICMS and OCR. Tumour morphology was coded using the International Classification of Diseases for Oncology (ICD-O), Second Edition, 1990 ([@bib36]). Data on tumour size (⩽0.5; \>0.5 to ⩽1.0; \>1.0 to ⩽2.0; \>2.0), nodal status (positive, negative), and stage (I, II, III) were collected for invasive cases. The TNM classification scheme ([@bib2]) was used for staging of breast cancer. Tumour size was defined as the largest diameter of the invasive carcinoma. Lymph node status was defined by TNM criteria for women who had axillary assessment.

Statistical analysis
--------------------

Risk factors and screening characteristics were compared between BAC and UC using multivariable logistic regression analyses, adjusted for age and/or year of screening. Similarly, the association of pathway (BAC/UC) with assessment and prognostic characteristics was examined using multivariable logistic regression to estimate adjusted odds ratios (ORs) and corresponding 95% confidence intervals (CIs) ([@bib13]). The association of risk, screening, assessment, and prognostic characteristics with delay in diagnosis (⩽7 weeks *vs* \>7 weeks) was examined separately for women assessed through BAC and UC to identify possible effect modification. Additional analyses examined stage and tumour size as quantitative exposure variables to assess trend effects. Wilcoxon rank-sum tests were used to test for differences in median time to diagnosis between pathways, overall and stratified by ⩽3 and \>3 procedures ([@bib15]). Finally, sensitivity analyses were performed on a subset of the cohort screened between 2006 and 2009 to examine whether differences between pathways persisted over time. All analyses were performed using SAS version 9.4 ([@bib30]). Statistical tests were two sided and evaluated at a 5% significance level.

Results
=======

Of the 155 866 women with an abnormal mammogram, 9702 (6.2%) were diagnosed with breast cancer. Women were excluded if they resided outside Ontario (*n*=29), had stage IV (*n*=94), bilateral (*n*=192) or non-primary (*n*=333) breast cancer, or had a breast cancer diagnosis \>1 year following an abnormal mammogram (*n*=10). The final sample included 9044 (93.2%) eligible women, of whom 4217 (47%) were assessed through a BAC and 4827 (53%) through UC ([Figure 1](#fig1){ref-type="fig"}).

The mean age at screening was 59.7 years, with no significant differences in age group distribution between pathways ([Table 1](#tbl1){ref-type="table"}). Women evaluated in a BAC compared with UC were more likely to have their abnormal mammogram be a rescreen than an initial screen, have their abnormal mammogram after 2006 than before, and be assessed with digital rather than screen-film mammography. Family history of breast or ovarian cancer, menopausal status, and age at menarche did not differ between pathways. Women assessed through a BAC were less likely to be parous *vs* nulliparous regardless of age, and were significantly more likely to have less mammographically dense breasts (\<75% *vs* ⩾75%) compared with UC. In addition, women assessed through a BAC were twice as likely to live in rural remote compared with urban regions, and less likely to be in the highest compared with lowest income quintile.

Compared with women assessed through UC, those assessed through a BAC were significantly more likely to have their first assessment procedure within 3 weeks of their abnormal mammogram (*vs* \>3; OR=1.25, 95% CI=1.12--1.39), ⩽3 assessment procedures (*vs* \>3; OR=1.54, 95% CI=1.41--1.69), ⩽2 assessment visits (*vs* \>2; OR=1.86, 95% CI=1.70--2.05), and ⩾2 procedures per visit (*vs* \<2; OR=1.41, 95% CI=1.28--1.55) ([Table 2](#tbl2){ref-type="table"}). In addition, women assessed through a BAC were more likely than those in UC to have imaging (OR=1.99, 95% CI=1.44--2.75) or a biopsy (OR=3.69, 95% CI=2.64--5.15) *vs* consultation only at their first assessment visit. Women diagnosed at a BAC were two times more likely to have a core or FNA biopsy than a surgical biopsy (OR=2.08, 95% CI=1.81--2.40), and almost twice as likely to receive a diagnosis within 7 weeks of their abnormal mammogram (*vs* \>7 weeks; OR=1.91, 95% CI=1.73--2.10) compared with those in UC. Sensitivity analyses on a subset of the cohort screened between 2006 and 2009 found similar results ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Prognostic characteristics did not significantly differ between pathways.

Irrespective of pathway, women with breast cancer were more likely to be diagnosed within 7 weeks if they had their first procedure within 3 weeks, ⩾2 assessment procedures per visit, a biopsy during their first assessment visit compared with a consultation only, and a core/FNA compared with surgical biopsy at any visit ([Table 3](#tbl3){ref-type="table"}). In addition, women having an invasive breast cancer *vs* DCIS, stage II or III *vs* stage I, a larger tumour size (\>0.5 *vs* ⩽0.5 cm), and positive *vs* negative nodal status were more likely to be diagnosed within 7 weeks, regardless of pathway. More advanced stage and larger tumour size increased the odds of being diagnosed within 7 weeks (test for trend *P*\<0.0001). Rurality decreased the likelihood of receiving a diagnosis within 7 weeks for both BAC and UC. Income quintile did not affect time to diagnosis in a BAC; however, women in the two highest quintiles (*vs* the lowest) were more likely to receive a diagnosis in 7 weeks (*vs* \>7) when assessed through UC. Having ⩽2 assessment visits was more likely to reduce time to diagnosis for women assessed through a BAC (OR=10.58, 95% CI=8.96--12.50) compared with UC (OR=4.47, 95% CI=3.94--5.07), as was having ⩽3 assessment procedures (*vs* \>3) (BAC OR=4.97, 95% CI=4.26--5.79; UC OR=2.95, 95% CI=2.61--3.73) ([Table 3](#tbl3){ref-type="table"}). Sensitivity analyses on a subset of the cohort screened between 2006 and 2009 found similar results ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}).

Overall median wait times from abnormal screen to diagnosis were 28 days for women assessed through BACs and 39 days for UC (*P*\<0.0001; [Figure 2](#fig2){ref-type="fig"}). For women with ⩽3 assessment procedures, the median time to diagnosis was 9 days shorter in a BAC compared with UC (BAC: 23 median days IQR=15--39; UC: 32 median days IQR=18--51; *P*\<0.0001) ([Figure 3](#fig3){ref-type="fig"}). Among women with \>3 procedures, this difference still persisted (BAC: 45 median days IQR=26--75; UC: 50 median days IQR=34--79; *P*\<0.0001).

Discussion
==========

This study found that women with breast cancer were almost two times more likely to be diagnosed within 7 weeks when assessed through a BAC *vs* UC. Irrespective of assessment pathway, women were significantly more likely to be diagnosed within 7 weeks if they had their first assessment procedure within 3 weeks (*vs* \>3 weeks), ⩾2 procedures per visit (*vs* \<2), a biopsy at first visit compared with consultation only, and a core/FNA compared with open biopsy at any visit. Having ⩽2 assessment visits and ⩽3 assessment procedures was more likely to reduce time to diagnosis for women assessed through a BAC compared with UC. However, diagnostic wait time was significantly shorter in a BAC, regardless of the number of procedures.

Another Ontario study found that women undergoing organised assessment had 1.7 times greater odds of receiving a diagnosis within 7 weeks ([@bib18]), a result very similar to this study. Although the previous study included only 1 year of data, a large proportion of opportunistic screens, and only invasive cancers, this study and ours suggests that organised assessment is beneficial to women. Shorter diagnostic intervals were also seen among women with screen-detected breast cancer in Manitoba who received diagnostic work up through direct referral compared with UC ([@bib12]). Women in British Columbia's direct referral program, ''Fast Track'', experienced similar improvement ([@bib6]), as did those receiving patient navigation in Nova Scotia ([@bib27]). Given our study, and others ([@bib23]; [@bib12]; [@bib27]; [@bib6]; [@bib4]; [@bib18]), it appears that patient navigation and coordinated referral results in equitable expedited access to services, having a consistent benefit over UC.

Having ⩽2 assessment visits and ⩽3 assessment procedures was more likely to reduce time to diagnosis for women assessed through a BAC *vs* UC. For women with ⩽ 3 assessment procedures, this difference could not be explained by time to first assessment procedure, which was similar between pathways. However, those in a BAC did have more procedures per visit than UC, resulting in more efficient visits. Women assessed through BACs also had assessment procedures scheduled in shorter intervals. In addition, type of procedure is important in shortening diagnostic wait times, as women assessed through BAC were more likely to have imaging or biopsy on their first assessment visit.

We found that open biopsy was uncommon overall, possibly because of the recommendation that tissue diagnosis of breast abnormalities be obtained before surgery ([@bib19]; [@bib5]). Irrespective of pathway, those who underwent open biopsy were more likely to experience longer wait times to diagnosis than those having percutaneous FNA or core biopsy. This finding is consistent with research conducted in British Columbia ([@bib25]) and across screening programs in Canada, including Ontario ([@bib22]). Wait times for operating rooms and the need for surgical consultations may be the most likely explanation for the delay. Recent findings have shown that women in rural areas have higher rates of open biopsy at diagnosis ([@bib16]). Although women attending BACs were more likely to live in rural areas, they had a lower proportion of open biopsies as a result of the standardisation of care pathways and improving access to guideline-based care. This in turn is likely to influence time to diagnosis ([@bib25], [@bib22]). In addition, although those in UC were more likely to be diagnosed within 7 weeks if they were of higher income, income had no effect for women assessed within a BAC. This result might indicate an important benefit of organised assessment on social disparities.

Irrespective of pathway, women with invasive breast cancers of more advanced stage and larger tumour size were more likely to be diagnosed within 7 weeks as compared with those diagnosed at earlier stages with smaller tumours. This finding is consistent with literature demonstrating an expedited evaluation process for more overtly worrisome cases, where suspicious ([@bib10]; [@bib24]; [@bib14]) and larger tumours ([@bib3]) were associated with decreased likelihood of diagnostic delay, and smaller tumours associated with increased delay ([@bib20]). Our results also align with research showing that women with less advanced stage were more likely to experience diagnostic delay compared with those with more advanced stage ([@bib18]), although their population also included symptomatic breast cancers.

Overall, women assessed through a BAC had more timely diagnoses and received fewer, more appropriate procedures. However, there are important considerations to facilitate the establishment of organised breast assessment centres. In Ontario, BACs require additional practitioners, access to diagnostic specialists, and adequate imaging, biopsy, and pathological assessment capacity ([@bib28]; [@bib18]). These requirements may be more challenging in remote settings, in addition to being more costly.

The strengths of this study include its use of existing data collected on a large population-based cohort of screened women during an 8-year period. All eligible women were identified from a centralised screening database, and follow-up was identical. Women diagnosed through BACs were similar to women diagnosed through UC by age at screen and at diagnosis and on breast cancer risk factors and prognostic characteristics. However, the two cohorts did differ significantly by year of screen and region of screening centre as this would reflect when and where the BACs were implemented. To ensure comparability, any differences in year of screen, screen type, mammography type, mammographic density, income quintile, and community status were adjusted for in analyses.

There were several limitations to the study. First, it was not possible to distinguish between system-level and certain patient-level factors associated with diagnostic delay. Patient-level factors that can influence diagnostic times include poorer health ([@bib38]), patient beliefs and attitudes ([@bib38]; [@bib1]), and logistical barriers to accessing services ([@bib1]). However, recent reviews have not been able to estimate the proportion of diagnostic delay that might be due to patient *vs* system-level factors ([@bib37]; [@bib39]). In addition, compared with UC, a greater proportion of women in the BAC cohort were seen in a more recent time period, when percutaneous biopsy has become standardised and more accessible. Lastly, this study focussed solely on patients with cancer diagnoses. We are not able to determine how diagnostic wait times would compare for patients with a benign outcome who often undergo less prompt assessment than those with overtly suspicious findings.

The benefits of early detection by mammography are dependent on women with abnormal screening results having access to timely and accurate diagnostic assessment. This study examined the impact of procedures and visits on diagnostic delays and found that women with screen-detected breast cancer in OBSP were more likely to have shorter wait times if they were seen through organised assessment. This was likely because of fewer, timelier, more appropriate assessment procedures for women diagnosed through BACs *vs* UC. Given the significant improvement in timeliness to diagnosis, women with abnormal mammograms should be managed through organised assessment. Future work will address the impact of diagnostic and treatment intervals on breast cancer survival by assessment pathway.

We thank the study staff: Leanne Lindsay, Lucy Leon, and Anjali Pandya. We also thank Cancer Care Ontario for use of its data. This work was supported by the Canadian Institutes of Health Research (Grant Number 130400). This agency had no involvement in the study design, data collection, analysis, interpretation, manuscript preparation, or the decision to submit the manuscript for publication.

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

The authors declare no conflict of interest.

Supplementary Material {#sup1}
======================

###### 

Click here for additional data file.

###### 

Click here for additional data file.

![Cohorts of women screened between 1 January 2002 and 31 December 2009 and diagnosed with breast cancer within the Ontario Breast Screening Program.](bjc201787f1){#fig1}

![Distributions of time to diagnosis (in days) for women diagnosed through Breast Assessment Centres and Usual Care.](bjc201787f2){#fig2}

![Median time and 90th percentile (in days) from abnormal mammogram to diagnosis for women diagnosed with screen-detected breast cancers, stratified by assessment centre type and number of assessment procedures (⩽3 assessments (top) *vs* \>3 assessments (bottom)). Sample size within the assessment boxes represent the proportion of women who have had that assessment (i.e., who have not yet obtained a diagnosis). ^a^Wilcoxon rank-sum test for differences in median days to diagnosis (23 days *vs* 31 days) for ⩽3 assessment procedures, *p*\<0.0001. ^b^Wilcoxon rank-sum test for differences in median days to diagnosis (45 days *vs* 50 days) for \> 3 assessment procedures, *p*\<0.0001.](bjc201787f3){#fig3}

###### Adjusted ORs and 95% CIs for the association of risk factors and screening characteristics among women diagnosed with screen-detected breast cancers through a Breast Assessment Centre compared with Usual Care

                                                                                          **Breast assessment type**                                                                                                                                                            
  --------------------------------------------------------------------------- --------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------ -------------------------- -------------------
  **Characteristics**                                                          **Usual Care,** ***N*****=4827,** ***n*** **(%)**   **Breast Assessment Centre,** ***N*****=4217,** ***n*** **(%)**   **Overall,** ***N*****=9044,** ***n*** **(%)**   **Adjusted OR (95% CI)**   ***P*****-value**
  **Age at screening (years)[a](#t1-fn2){ref-type="fn"}**                                                                                                                                                                                                                       
  50--59                                                                                          2335 (48.4)                                                2045 (48.5)                                              4380 (48.4)                         1.00 (reference)                
  60--69                                                                                          2492 (51.6)                                                2172 (51.5)                                              4664 (51.6)                        0.98 (0.90--1.06)            0.6170
  **Screen type[b](#t1-fn3){ref-type="fn"}**                                                                                                                                                                                                                                    
  Initial                                                                                         1859 (38.5)                                                1230 (29.2)                                              3089 (34.2)                         1.00 (reference)                
  Rescreen                                                                                        2968 (61.5)                                                2987 (70.8)                                              5955 (65.8)                        1.55 (1.41--1.70)           \<0.0001
  **Period of screening[c](#t1-fn4){ref-type="fn"}**                                                                                                                                                                                                                            
  2002--2005                                                                                      2060 (42.7)                                                1364 (32.3)                                              3424 (37.9)                         1.00 (reference)                
  2006--2009                                                                                      2767 (57.3)                                                2853 (67.7)                                              5620 (62.1)                        1.56 (1.43--1.70)           \<0.0001
  **Mammography type[b](#t1-fn3){ref-type="fn"}**                                                                                                                                                                                                                               
  Screen film                                                                                     4315 (89.4)                                                3325 (78.9)                                              7640 (84.5)                         1.00 (reference)                
  Digital                                                                                         512 (10.6)                                                 892 (21.1)                                               1404 (15.5)                        1.89 (1.66--2.15)           \<0.0001
  **Family history of breast or ovarian cancer[b](#t1-fn3){ref-type="fn"}**                                                                                                                                                                                                     
  No                                                                                              3799 (78.7)                                                3251 (77.1)                                              7050 (78.0)                         1.00 (reference)                
  Yes                                                                                             1028 (21.3)                                                966 (22.9)                                               1994 (22.0)                        1.09 (0.98--1.20)            0.1002
  **Menopausal status[b](#t1-fn3){ref-type="fn"}**                                                                                                                                                                                                                              
  Premenopausal                                                                                   709 (14.7)                                                 608 (14.4)                                               1317 (14.6)                         1.00 (reference)                
  Postmenopausal                                                                                  4117 (85.3)                                                3609 (85.6)                                              7726 (85.4)                        1.00 (0.88--1.14)            0.9949
  Missing                                                                                              1                                                          0                                                        1                                     --                       
  **Age at menarche (years) [b](#t1-fn3){ref-type="fn"}**                                                                                                                                                                                                                       
  ⩽11                                                                                             874 (18.8)                                                 814 (20.0)                                               1688 (19.3)                         1.00 (reference)                
  \>11                                                                                            3786 (81.2)                                                3261 (80.0)                                              7047 (80.7)                        0.92 (0.82--1.02)            0.1170
  Missing                                                                                             167                                                        142                                                      309                                    --                       
  **Parity[b](#t1-fn3){ref-type="fn"}**                                                                                                                                                                                                                                         
  Nulliparous                                                                                      70 (1.7)                                                   91 (2.5)                                                 161 (2.1)                          1.00 (reference)                
  Age at FFTP \<30                                                                                3481 (83.5)                                                3056 (83.7)                                              6537 (83.6)                        0.70 (0.51--0.96)            0.0270
  Age at FFTP ⩾30                                                                                 617 (14.8)                                                 503 (13.8)                                               1120 (14.3)                        0.63 (0.45--0.88)            0.0066
  Missing                                                                                             659                                                        567                                                      1226                                   --                       
  **Mammographic density (%)[b](#t1-fn3){ref-type="fn"}**                                                                                                                                                                                                                       
  ⩾75%                                                                                             456 (9.4)                                                  311 (7.4)                                                767 (8.5)                          1.00 (reference)                
  \<75%                                                                                           4371 (90.6)                                                3906 (92.6)                                              8277 (91.5)                        1.34 (1.15--1.56)            0.0002
  **Community status[b](#t1-fn3){ref-type="fn"}**                                                                                                                                                                                                                               
  Urban                                                                                           4117 (85.3)                                                3477 (82.5)                                              7594 (84.0)                         1.00 (reference)                
  Rural                                                                                            297 (6.2)                                                  214 (5.1)                                                511 (5.6)                         0.87 (0.73--1.05)            0.1491
  Rural remote                                                                                     234 (4.8)                                                  406 (9.6)                                                640 (7.1)                         2.13 (1.80--2.52)           \<0.0001
  Rural very remote                                                                                177 (3.7)                                                  119 (2.8)                                                296 (3.3)                         0.80 (0.63--1.02)            0.0711
  Missing                                                                                              2                                                          1                                                        3                                                              
  **Income quintile[b](#t1-fn3){ref-type="fn"}**                                                                                                                                                                                                                                
  1, Lowest                                                                                       771 (16.1)                                                 735 (17.5)                                               1506 (16.7)                         1.00 (reference)                
  2                                                                                               912 (19.0)                                                 842 (20.1)                                               1754 (19.5)                        0.96 (0.84--1.10)            0.5626
  3                                                                                               934 (19.4)                                                 804 (19.1)                                               1738 (19.3)                        0.90 (0.78--1.03)            0.1216
  4                                                                                               988 (20.6)                                                 848 (20.2)                                               1836 (20.4)                        0.88 (0.77--1.01)            0.0691
  5, Highest                                                                                      1195 (24.9)                                                970 (23.1)                                               2165 (24.1)                        0.85 (0.74--0.97)            0.0132
  Missing                                                                                             27                                                         18                                                        45                                    --                       

Abbreviations: CI=confidence interval; FTTP=first full-term pregnancy; OR=odds ratio.

Adjusted by year of screen.

Adjusted by year of screen and age at screening.

Adjusted by age at screening.

###### Adjusted ORs and 95% CIs for association of assessment and prognostic characteristics among women diagnosed with screen-detected breast cancers through a Breast Assessment Centre compared with Usual Care

                                           **Breast assessment type**                                                   
  ---------------------------------------- ---------------------------- ------------- ------------- ------------------- ----------
  **Time to first assessment procedure**                                                                                
  \>3 Weeks                                1056 (21.9)                  794 (18.8)    1850 (20.5)    1.00 (reference)    
  ⩽3 Weeks                                 3771 (78.1)                  3423 (81.2)   7194 (79.5)    1.25 (1.12--1.39)  \<0.0001
  **Total assessment procedures**                                                                                       
  \>3 Procedures                           2034 (42.1)                  1336 (31.7)   3370 (37.3)    1.00 (reference)    
  ⩽3 Procedures                            2793 (57.9)                  2881 (68.3)   5674 (62.7)    1.54 (1.41--1.69)  \<0.0001
  **Total assessment visits**                                                                                           
  \>2 Visits                               1918 (39.7)                  1089 (25.8)   3007 (33.2)    1.00 (reference)    
  ⩽2 Visits                                2909 (60.3)                  3128 (74.2)   6037 (66.8)    1.86 (1.70--2.05)  \<0.0001
  **Procedures per visit (average)**                                                                                    
  \<2 Procedures per visit                 3617 (74.9)                  2895 (68.6)   6512 (72.0)    1.00 (reference)    
  ⩾2 Procedures per visit                  1210 (25.1)                  1322 (31.4)   2532 (28.0)    1.41 (1.28--1.55)  \<0.0001
  **Procedure(s) at first visit**                                                                                       
  Consultation only                        148 (3.1)                    54 (1.3)      202 (2.2)      1.00 (reference)    
  Imaging (±consultation)                  3944 (81.7)                  3129 (74.2)   7073 (78.2)    1.99 (1.44--2.75)  \<0.0001
  Biopsy (±imaging or consultation)        735 (15.2)                   1034 (24.5)   1769 (19.6)    3.69 (2.64--5.15)  \<0.0001
  **First biopsy procedure (any visit)**                                                                                
  Open/surgical                            787 (16.3)                   346 (8.2)     1133 (12.5)    1.00 (reference)    
  Core/FNA                                 4038 (83.7)                  3870 (91.8)   7908 (87.5)    2.08 (1.81--2.40)  \<0.0001
  Missing                                  2                            1             3                     --           
  **Time to diagnosis**                                                                                                 
  \>7 weeks                                1776 (36.8)                  1004 (23.8)   2780 (30.7)    1.00 (reference)    
  ⩽7 weeks                                 3051 (63.2)                  3213 (76.2)   6264 (69.3)    1.91 (1.73--2.10)  \<0.0001
  **Age at diagnosis (years)**                                                                                          
  50--59                                   2299 (47.6)                  2025 (48.0)   4324 (47.8)    1.00 (reference)    
  60--70                                   2528 (52.4)                  2192 (52.0)   4720 (52.2)    0.89 (0.75--1.05)  0.1552
  **Breast cancer classification**                                                                                      
  DCIS                                     920 (19.1)                   810 (19.2)    1730 (19.1)    1.00 (reference)    
  Invasive                                 3907 (80.9)                  3407 (80.8)   7314 (80.9)    1.00 (0.90--1.11)  0.9669
  **Invasive stage at diagnosis**                                                                                       
  Stage I                                  2301 (63.4)                  2030 (62.7)   4331 (63.1)    1.00 (reference)    
  Stage II                                 1135 (31.2)                  1018 (31.5)   2153 (31.3)    1.03 (0.92--1.14)  0.6375
  Stage III                                195 (5.4)                    189 (5.8)     384 (5.6)      1.02 (0.82--1.26)  0.8898
  Missing                                  276                          170           446                   --           
  **Invasive tumour size**                                                                                              
  ⩽0.5 cm (T1mic, T1a)                     345 (9.5)                    279 (9.0)     624 (9.3)      1.00 (reference)    
  \>0.5--⩽1.0 (T1b)                        853 (23.6)                   782 (25.2)    1635 (24.3)    1.11 (0.92--1.34)  0.2862
  \>1.0--⩽2.0 (T1c)                        1538 (42.5)                  1295 (41.7)   2833 (42.2)    1.01 (0.85--1.21)  0.9076
  \>2.0 (T2, T3, T4)                       879 (24.3)                   748 (24.1)    1627 (24.2)    1.02 (0.84--1.23)  0.8795
  Missing                                  292                          303           595                                
  **Invasive nodal status**                                                                                             
  Negative                                 2682 (76.3)                  2404 (75.2)   5086 (75.8)    1.00 (reference)    
  Positive                                 835 (23.7)                   791 (24.8)    1626 (24.2)    1.05 (0.94--1.18)  0.3938
  Missing                                  390                          212           602                   --           

Abbreviations: CI=confidence interval; DCIS=ductal carcinoma *in situ*; FNA=fine-needle aspiration; OR=odds ratio.

Adjusted by year of screen, age at screening, screen type (initial *vs* rescreen), mammography type (film *vs* digital), mammographic density, income quintile, and community status.

###### Adjusted ORs and 95% CIs for the association of breast cancer risk factors, screening, assessment, and prognostic characteristics by time to diagnosis (⩽7 *vs* \>7 weeks) among women diagnosed with screen-detected breast cancers through a Breast Assessment Centre and Usual Care

                                                                      **Breast Assessment Centre (*****n*****=4217)**   **Usual Care (*****n*****=4827)**                                                                                
  ------------------------------------------------------------------- ------------------------------------------------- ----------------------------------- ------------------------------------------------ ------------- ------------- ----------------------------------------------
  **Screen type[a](#t3-fn2){ref-type="fn"}**                                                                                                                                                                                             
  Initial                                                             289 (28.8)                                        941 (29.3)                                          1.00 (reference)                 673 (37.9)    1186 (38.9)                  1.00 (reference)
  Rescreen                                                            715 (71.2)                                        2272 (70.7)                                        0.97 (0.82--1.15)                 1103 (62.1)   1865 (61.1)                 0.96 (0.85--1.09)
  **Mammography type[a](#t3-fn2){ref-type="fn"}**                                                                                                                                                                                        
  Screen film                                                         782 (77.9)                                        2543 (79.1)                                         1.00 (reference)                 1604 (90.3)   2711 (88.9)                  1.00 (reference)
  Digital                                                             222 (22.1)                                        670 (20.9)                                         1.12 (0.92--1.36)                 172 (9.7)     340 (11.1)                  1.12 (0.91--1.38)
  **Mammographic density[a](#t3-fn2){ref-type="fn"}**                                                                                                                                                                                    
  \<75%                                                               915 (91.1)                                        2991 (93.1)                                         1.00 (reference)                 1600 (90.1)   2771 (90.8)                  1.00 (reference)
  ⩾75%                                                                89 (8.9)                                          222 (6.9)                                          0.78 (0.60--1.01)                 176 (9.9)     280 (9.2)                   0.91 (0.74--1.11)
  **Community status[a](#t3-fn2){ref-type="fn"}**                                                                                                                                                                                        
  Urban                                                               756 (75.3)                                        2721 (84.7)                                         1.00 (reference)                 1500 (84.5)   2617 (85.8)                  1.00 (reference)
  Rural                                                               58 (5.8)                                          156 (4.9)                                          0.75 (0.55--1.03)                 93 (5.2)      204 (6.7)                   1.27 (0.98--1.63)
  Rural remote                                                        128 (12.7)                                        278 (8.7)                             0.60 (0.48--0.75)[d](#t3-fn5){ref-type="fn"}   102 (5.8)     132 (4.3)                  0.75 (0.58--0.98)^e^
  Rural very remote                                                   62 (6.2)                                          57 (1.8)                              0.26 (0.18--0.37)[d](#t3-fn5){ref-type="fn"}   80 (4.5)      97 (3.2)                   0.70 (0.52--0.95)^f^
  Missing                                                             0                                                 1                                                          --                        1             1                                   --
  **Income quintile[a](#t3-fn2){ref-type="fn"}**                                                                                                                                                                                         
  1, Lowest                                                           176 (17.6)                                        559 (17.5)                                          1.00 (reference)                 309 (17.5)    462 (15.2)                   1.00 (reference)
  2                                                                   235 (23.6)                                        607 (19.0)                                         0.83 (0.66--1.04)                 330 (18.7)    582 (19.2)                  1.18 (0.97--1.44)
  3                                                                   169 (17.0)                                        635 (19.8)                                         1.19 (0.94--1.52)                 361 (20.5)    573 (18.9)                  1.06 (0.87--1.29)
  4                                                                   195 (19.6)                                        653 (20.4)                                         1.07 (0.84--1.35)                 347 (19.7)    641 (21.1)                 1.23 (1.01--1.49)^g^
  5, Highest                                                          222 (22.3)                                        748 (23.4)                                         1.07 (0.85--1.34)                 418 (23.7)    777 (25.6)                 1.24 (1.03--1.50)^h^
  Missing                                                             7                                                 11                                                         --                        11            16                                  --
  **Time to first assessment procedure[b](#t3-fn2){ref-type="fn"}**                                                                                                                                                                      
  \>3 Weeks                                                           387 (38.5)                                        407 (12.7)                                          1.00 (reference)                 706 (39.8)    350 (11.5)                   1.00 (reference)
  ⩽3 Weeks                                                            617 (61.5)                                        2806 (87.3)                           4.18 (3.53--4.94)[d](#t3-fn5){ref-type="fn"}   1070 (60.3)   2701 (88.5)    5.12 (4.41--5.93)[d](#t3-fn5){ref-type="fn"}
  **Total assessment procedures[b](#t3-fn2){ref-type="fn"}**                                                                                                                                                                             
  \>3 Procedures                                                      595 (59.3)                                        741 (23.1)                                          1.00 (reference)                 1039 (58.5)   995 (32.6)                   1.00 (reference)
  ⩽3 Procedures                                                       409 (40.7)                                        2472 (76.9)                           4.97 (4.26--5.79)[d](#t3-fn5){ref-type="fn"}   737 (41.5)    2056 (67.4)    2.95 (2.61--3.33)[d](#t3-fn5){ref-type="fn"}
  **Total assessment visits[b](#t3-fn2){ref-type="fn"}**                                                                                                                                                                                 
  \>2 Visits                                                          632 (62.9)                                        457 (14.2)                                          1.00 (reference)                 1098 (61.8)   820 (26.9)                   1.00 (reference)
  ⩽2 Visits                                                           372 (37.1)                                        2756 (85.8)                          10.58 (8.96--12.50)[d](#t3-fn5){ref-type="fn"}  678 (38.2)    2231 (73.1)    4.47 (3.94--5.07)[d](#t3-fn5){ref-type="fn"}
  Average number of procedures per visit[b](#t3-fn2){ref-type="fn"}                                                                                                                                                                      
  \<2 Procedures per visit                                            883 (88.0)                                        2012 (62.6)                                         1.00 (reference)                 1546 (87.1)   2071 (6.9)                   1.00 (reference)
  ⩾2 Procedures per visit                                             121 (12.1)                                        1201 (37.4)                           4.31 (3.51--5.29)[d](#t3-fn5){ref-type="fn"}   230 (13.0)    980 (32.1)     3.18 (2.71--3.73)[d](#t3-fn5){ref-type="fn"}
  **Procedure(s) at first visit[b](#t3-fn2){ref-type="fn"}**                                                                                                                                                                             
  Consultation only                                                   17 (1.7)                                          37 (1.2)                                            1.00 (reference)                 57 (3.2)      91 (3.0)                     1.00 (reference)
  Imaging (±consultation)                                             917 (91.3)                                        2212 (68.8)                                        1.12 (0.62--2.02)                 1651 (93.0)   2293 (75.2)                 0.84 (0.60--1.18)
  Biopsy (±imaging or consultation)                                   70 (7.0)                                          964 (30.0)                           6.00 (3.18--11.33)[d](#t3-fn5){ref-type="fn"}   68 (3.8)      667 (21.9)     6.05 (3.99--9.18)[d](#t3-fn5){ref-type="fn"}
  **First biopsy procedure (any visit)[b](#t3-fn2){ref-type="fn"}**                                                                                                                                                                      
  Open/surgical                                                       150 (14.9)                                        196 (6.1)                                           1.00 (reference)                 429 (24.2)    358 (11.7)                   1.00 (reference)
  Core/FNA                                                            854 (85.1)                                        3016 (93.9)                                       2.85 (2.25--3.61)^d^               1346 (75.8)   2692 (88.3)    2.43 (2.06--2.86)[d](#t3-fn5){ref-type="fn"}
  Missing                                                             0                                                 1                                                          --                        1             1                                   --
  **Age at diagnosis (years)[c](#t3-fn3){ref-type="fn"}**                                                                                                                                                                                
  50--59                                                              475 (47.3)                                        1550 (48.2)                                         1.00 (reference)                 833 (46.9)    1466 (48.0)                  1.00 (reference)
  60--70                                                              529 (52.7)                                        1663 (51.8)                                        0.98 (0.85--1.13)                 943 (53.1)    1585 (52.0)                 0.95 (0.85--1.07)
  **Breast cancer classification[b](#t3-fn2){ref-type="fn"}**                                                                                                                                                                            
  DCIS                                                                305 (30.4)                                        505 (15.7)                                          1.00 (reference)                 482 (27.1)    438 (14.4)                   1.00 (reference)
  Invasive                                                            699 (69.6)                                        2708 (84.3)                           2.41 (2.03--2.85)[d](#t3-fn5){ref-type="fn"}   1294 (72.9)   2613 (85.6)    2.26 (1.95--2.62)[d](#t3-fn5){ref-type="fn"}
  **Invasive stage at diagnosis[b](#t3-fn2){ref-type="fn"}**                                                                                                                                                                             
  Stage I                                                             451 (70.8)                                        1579 (60.7)                                         1.00 (reference)                 836 (70.7)    1465 (59.8)                  1.00 (reference)
  Stage II                                                            158 (24.8)                                        860 (33.1)                            1.58 (1.29--1.93)[d](#t3-fn5){ref-type="fn"}   307 (26.0)    828 (33.8)     1.55 (1.32--1.81)[d](#t3-fn5){ref-type="fn"}
  Stage III                                                           28 (4.4)                                          161 (6.2)                                         1.82 (1.19--2.79)^i^               40 (3.4)      155 (6.3)      2.14 (1.49--3.08)[d](#t3-fn5){ref-type="fn"}
  Missing                                                             62                                                108                                                        --                        111           165                                 --
  **Invasive tumour size[b](#t3-fn2){ref-type="fn"}**                                                                                                                                                                                    
  ⩽0.5 cm (T1mic, T1a)                                                87 (14.2)                                         192 (7.7)                                           1.00 (reference)                 167 (14.0)    178 (7.3)                    1.00 (reference)
  \>0.5--⩽1.0 (T1b)                                                   190 (31.1)                                        592 (23.8)                                        1.47 (1.09--2.00)^j^               347 (29.1)    506 (20.9)                 1.36 (1.06--1.75)^k^
  \>1.0--⩽2.0 (T1c)                                                   235 (38.5)                                        1060 (42.5)                           2.17 (1.62--2.91)[d](#t3-fn5){ref-type="fn"}   460 (38.6)    1078 (44.5)    2.19 (1.73--2.79)[d](#t3-fn5){ref-type="fn"}
  \>2.0 (T2, T3, T4)                                                  99 (16.2)                                         649 (26.0)                            3.18 (2.28--4.45)[d](#t3-fn5){ref-type="fn"}   217 (18.2)    662 (27.3)     2.84 (2.18--3.69)[d](#t3-fn5){ref-type="fn"}
  Missing                                                             88                                                215                                                        --                        103           189                                 --
  **Invasive nodal status[b](#t3-fn2){ref-type="fn"}**                                                                                                                                                                                   
  Negative                                                            502 (79.2)                                        1902 (74.3)                                         1.00 (reference)                 930 (81.7)    1752 (73.7)                  1.00 (reference)
  Positive                                                            132 (20.8)                                        659 (25.7)                                        1.38 (1.11--1.71)^l^               209 (18.3)    626 (26.3)     1.59 (1.33--1.89)[d](#t3-fn5){ref-type="fn"}
  Missing                                                             65                                                147                                                        --                        155           235                                 --

Abbreviations: CI=confidence interval; DCIS=ductal carcinoma *in situ*; FNA=fine-needle aspiration; OR=odds ratio.

Adjusted by year of screen and age at screening.

Adjusted by year of screen, age at screening, income quintile, and community status.

Adjusted by year of screen, income quintile, and community status.

*P*\<0.0001; ^e^*P*=0.0362; ^f^*P*=0.0211; ^g^*P*=0.0386; ^h^*P*=0.0231; ^i^ *P*=0.0058; ^j^*P*=0.0131; ^k^*P*=0.0175; ^l^*P*=0.0105.
